Floatz logo

Azithromycin

Mycobacterium Abscessus Pulmonary Disease

The University of QueenslandSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Mycobacterium Abscessus Pulmonary Disease cohort.

Asset / SponsorPhaseRating
RIFABUTIN
The University of Queensland
Phase 2CCC
Trimethoprim
The University of Queensland
Phase 2CCC
Molgramostim Nebulizer
Savara Inc.
Phase 2CCC
CEFOXITIN
The University of Queensland
Phase 2CCC
Amikacin
The University of Queensland
Phase 2CCC

View all 22 →

Same molecule, other indications

Azithromycin is also rated in:

bronchiectasisDormant
BBB
Indicative ·
73 / 100
View asset →
cystic fibrosisDormant
BBB
Indicative ·
72 / 100
View asset →
dry eye syndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →